Travere Therapeutics Inc [TVTX] stock prices are up 0.18% to $16.94 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TVTX shares have gain 8.38% over the last week, with a monthly amount glided 2.36%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Citigroup reaffirmed its Buy rating on June 11, 2025, and dropped its price target to $32. On January 10, 2025, Cantor Fitzgerald initiated with a Overweight rating. Wells Fargo upgraded its rating to a Overweight and increased its price target to $27 on October 21, 2024. Scotiabank initiated its recommendation with a Sector Outperform. Guggenheim upgraded its rating to Buy for this stock on September 09, 2024, but kept the price target unchanged to $25. In a note dated March 27, 2024, Guggenheim downgraded an Neutral rating on this stock.
The stock price of Travere Therapeutics Inc [TVTX] has been fluctuating between $8.09 and $25.29 over the past year. Currently, Wall Street analysts expect the stock to reach $21.75 within the next 12 months. Travere Therapeutics Inc [NASDAQ: TVTX] shares were valued at $16.94 at the most recent close of the market. An investor can expect a potential return of 28.39% based on the average TVTX price forecast.
Analyzing the TVTX fundamentals
The Travere Therapeutics Inc [NASDAQ:TVTX] reported sales of 333.87M for trailing twelve months, representing a surge of 111.49%. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -0.51%, Pretax Profit Margin comes in at -0.51%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -0.3, Equity is -7.18 and Total Capital is -0.46. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 12.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Travere Therapeutics Inc [NASDAQ:TVTX]’s Current Ratio is 2.00. Also, the Quick Ratio is 1.98, while the Cash Ratio stands at 0.4. Considering the valuation of this stock, the price to sales ratio is 4.52, the price to book ratio is 46.09.
Transactions by insiders
Recent insider trading involved Inrig Jula, CHIEF MEDICAL OFFICER, that happened on Jul 01 ’25 when 815.0 shares were sold. CHIEF FINANCIAL OFFICER, Cline Christopher R. completed a deal on May 05 ’25 to sell 1784.0 shares. Meanwhile, CHIEF EXECUTIVE OFFICER Dube Eric M sold 18924.0 shares on May 05 ’25.
